How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?

My approach is to use rituximab every 6 months for remission maintenance for at least 2 years. Past that point, a lot depends on the individual patient circumstances. For patients who have already suffered substantial organ damage, for whom another flare could be catastrophic (e.g., a patient with s...

After remission induction of active disease with rituximab, I recommend remission maintenance therapy in almost all patients, given the high frequency of relapse in ANCA associated vasculitis. In shared decision-making with the patient, I discuss the options of rituximab or a conventional immunosupp...